Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?

Core Viewpoint - BioMarin Pharmaceutical (BMRN) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Group 1: Earnings Performance - BioMarin has a solid track record of surpassing earnings estimates, with an average surprise of 21.35% over the last two quarters [2]. - In the most recent quarter, BioMarin reported earnings of $0.92 per share, exceeding the expected$0.73 per share by 26.03% [3]. - For the previous quarter, the company reported $0.91 per share against an expectation of$0.78 per share, resulting in a surprise of 16.67% [3]. Group 2: Earnings Estimates and Predictions - Recent changes in earnings estimates for BioMarin have been favorable, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [6]. - The combination of a positive Earnings ESP and a Zacks Rank 2 (Buy) suggests that another earnings beat is likely [9]. - BioMarin currently has an Earnings ESP of +6.51%, reflecting increased analyst optimism regarding the company's earnings prospects [9]. Group 3: Importance of Earnings ESP - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate being more reflective of recent analyst revisions [8]. - It is crucial to check a company's Earnings ESP before quarterly releases to enhance the likelihood of successful investment decisions [10].